All participants recovered from the events, which were judged unlikely to be related to treatment, except for the vomiting, hypertension, 0 1 2 3 4 5 6 7 8 9 10(A) (B) (C) (D) (E) Mean semaglutide  concentration (nmol/L) Time (hours) Normal hepatic function Mild hepatic impairment Moderate hepatic impairment Severe hepatic impairment 0 168 336 504 672 84036 96 0 2 4 6 8 10 12 14 16 18 20 Time (hours) 0 168 336 504 672 84036 96 0 2 4 6 8 10 12 14 16 18 20 Time (hours) 0 168 336 504 672 84036 96 0 2 4 6 8 10 12 14 16 18 20 Time (hours) 0 168 336 504 672 84036 96 0 2 4 6 8 10 12 14 16 18 20 Time (hours) 0 168 336 504 672 84036 96 Normal hepatic function Mild hepatic impairment Moderate hepatic impairment Severe hepatic impairment Mean semaglutide concentration (nmol/L) Mean semaglutide concentration (nmol/L) FIGURE 1 Plasma semaglutide concentration–time profiles in participants with normal hepatic function and those with hepatic impairment after a single dose of subcutaneous semaglutide 0.5 mg. A, Geometric mean profiles. B–E, Individual participant profiles.